Phase II study of adozelesin in untreated metastatic breast cancer.

  title={Phase II study of adozelesin in untreated metastatic breast cancer.},
  author={Massimo Cristofanilli and William J. Bryan and Langdon L. Miller and Alex Yuang-chi Chang and William John Gradishar and Donald Kufe and Gabriel N Hortobagyi},
  journal={Anti-cancer drugs},
  volume={9 9},
Adozelesin is the first of a class of DNA-sequence-selective alkylating agents, the cyclopropa(c)pyrrolo(3,2-e)indol-4(5H)-ones (CPls), that have been shown to have of potent inhibitory properties of DNA synthesis. Based on preliminary data from phase I studies showing clinical activity in patients with breast cancer, we initiated a multicenter phase II study in untreated metastatic breast carcinoma. Adozelesin was administered at a starting dose of 150 microg/m2 as a single 10 min infusion per… CONTINUE READING


Publications citing this paper.
Showing 1-9 of 9 extracted citations

Similar Papers

Loading similar papers…